+

WO2002016585A3 - Nouveaux homologues du recepteur de l'imidazoline - Google Patents

Nouveaux homologues du recepteur de l'imidazoline Download PDF

Info

Publication number
WO2002016585A3
WO2002016585A3 PCT/US2001/025851 US0125851W WO0216585A3 WO 2002016585 A3 WO2002016585 A3 WO 2002016585A3 US 0125851 W US0125851 W US 0125851W WO 0216585 A3 WO0216585 A3 WO 0216585A3
Authority
WO
WIPO (PCT)
Prior art keywords
imrrp1
imrrp1b
imidazoline receptor
disorders
stimulation
Prior art date
Application number
PCT/US2001/025851
Other languages
English (en)
Other versions
WO2002016585A2 (fr
Inventor
John N Feder
Gabe Mintier
Gene G Kinney
Chandra S Ramanathan
Original Assignee
Bristol Myers Squibb Co
John N Feder
Gabe Mintier
Gene G Kinney
Chandra S Ramanathan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, John N Feder, Gabe Mintier, Gene G Kinney, Chandra S Ramanathan filed Critical Bristol Myers Squibb Co
Priority to JP2002522258A priority Critical patent/JP2004512830A/ja
Priority to CA002419919A priority patent/CA2419919A1/fr
Priority to EP01962245A priority patent/EP1317540A2/fr
Priority to AU2001283440A priority patent/AU2001283440A1/en
Priority to MXPA03001348A priority patent/MXPA03001348A/es
Priority to IL15431701A priority patent/IL154317A0/xx
Publication of WO2002016585A2 publication Critical patent/WO2002016585A2/fr
Publication of WO2002016585A3 publication Critical patent/WO2002016585A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Addiction (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention porte: sur de nouveaux homologues du récepteur de l'imidazoline; sur la protéine 1 (IMRRP1) désignée associée au récepteur de l'imidazoline; sur la protéine 1 (IMRRP1) associée au récepteur de l'imidazoline; et sur leurs dérivés; sur des préparations pharmaceutiques comprenant au moins une IMRRP1, une IMRRP1b ou au moins une de leurs parties fonctionnelles, et sur leurs procédés d'obtention. L'invention porte également sur des séquences d'acides nucléiques codant pour des polypeptides, des oligonucléotides, leurs fragments, parties ou molécules antisens et sur des vecteurs d'expression et cellules hôtes comprenant les polynucléotides codant pour l'IMRRP1 ou l'IMRRP1b, et en outre sur l'utilisation de séquences d'acides nucléiques, de polypeptide, peptide et anticorps pour le diagnostic et le traitement de troubles ou maladies associés à: une régulation aberrante de la tension artérielle, à l'induction de l'alimentation, à la stimulation de la décharge des neurones du locus coeruleus, à la stimulation de la libération d'insuline, à l'induction aberrante de l'expression de la protéine gliale fibrillaire acide, indépendante des adrénorécepteurs alpha-2, au syndrome prémenstruel dysphorique, aux troubles neurodégénératifs tels que la maladie d'Alzheimer, à la toxicomanie, au renouvellement de la monoamine et par là à la nociperception, au vieillissement, à l'humeur suivie d'accès, aux troubles de la salivation, et aux troubles du développement.
PCT/US2001/025851 2000-08-18 2001-08-17 Nouveaux homologues du recepteur de l'imidazoline WO2002016585A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2002522258A JP2004512830A (ja) 2000-08-18 2001-08-17 新規イミダゾリンレセプター相同体
CA002419919A CA2419919A1 (fr) 2000-08-18 2001-08-17 Nouveaux homologues du recepteur de l'imidazoline
EP01962245A EP1317540A2 (fr) 2000-08-18 2001-08-17 Nouveaux homologues du recepteur de l'imidazoline
AU2001283440A AU2001283440A1 (en) 2000-08-18 2001-08-17 Novel imidazoline receptor homologs
MXPA03001348A MXPA03001348A (es) 2000-08-18 2001-08-17 Homologos receptores novedosos de imidazolina.
IL15431701A IL154317A0 (en) 2000-08-18 2001-08-17 Imidazoline receptor homologs

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22641100P 2000-08-18 2000-08-18
US60/226,411 2000-08-18
US26177901P 2001-01-16 2001-01-16
US60/261,779 2001-01-16

Publications (2)

Publication Number Publication Date
WO2002016585A2 WO2002016585A2 (fr) 2002-02-28
WO2002016585A3 true WO2002016585A3 (fr) 2003-03-27

Family

ID=26920508

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/025851 WO2002016585A2 (fr) 2000-08-18 2001-08-17 Nouveaux homologues du recepteur de l'imidazoline

Country Status (8)

Country Link
US (1) US20020161191A1 (fr)
EP (1) EP1317540A2 (fr)
JP (1) JP2004512830A (fr)
AU (1) AU2001283440A1 (fr)
CA (1) CA2419919A1 (fr)
IL (1) IL154317A0 (fr)
MX (1) MXPA03001348A (fr)
WO (1) WO2002016585A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030215916A1 (en) * 2000-08-18 2003-11-20 Feder John N. Novel imidazoline receptor homologs
WO2002024750A2 (fr) * 2000-09-21 2002-03-28 Aeomica, Inc. Proteine membranaire humaine surexprimee dans une tumeur renale 1 (ktom1)
AU2003257418A1 (en) * 2002-06-19 2004-01-06 Solvay Pharmaceuticals Gmbh Medicament for the treatment of diseases requiring inhibition or a reduction in the activity of ph value-regulating bicarbonate transporter proteins
DE102007029008A1 (de) * 2007-06-23 2008-12-24 Bayer Materialscience Ag Verfahren zur Herstellung eines leitfähigen Polymerverbundwerkstoffs

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006548A2 (fr) * 1997-08-01 1999-02-11 Genset Est 5' pour proteines secretees sans specificite tissulaire
WO1999011668A1 (fr) * 1997-09-03 1999-03-11 The University Of Mississippi Medical Center Molecules d'adn codant des polypeptides receptifs a l'imidazoline et polypeptides codes par cet adn
WO2002024750A2 (fr) * 2000-09-21 2002-03-28 Aeomica, Inc. Proteine membranaire humaine surexprimee dans une tumeur renale 1 (ktom1)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020168711A1 (en) * 2000-01-31 2002-11-14 Rosen Craig A. Nucleic acids, proteins, and antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006548A2 (fr) * 1997-08-01 1999-02-11 Genset Est 5' pour proteines secretees sans specificite tissulaire
WO1999011668A1 (fr) * 1997-09-03 1999-03-11 The University Of Mississippi Medical Center Molecules d'adn codant des polypeptides receptifs a l'imidazoline et polypeptides codes par cet adn
WO2002024750A2 (fr) * 2000-09-21 2002-03-28 Aeomica, Inc. Proteine membranaire humaine surexprimee dans une tumeur renale 1 (ktom1)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] EBI Hinxton, UK; 8 February 2001 (2001-02-08), ADACHI J ET AL: "Functional annotation of a full-length mouse cDNA collection", XP002217273, Database accession no. AK004757 *

Also Published As

Publication number Publication date
JP2004512830A (ja) 2004-04-30
AU2001283440A1 (en) 2002-03-04
MXPA03001348A (es) 2004-04-05
US20020161191A1 (en) 2002-10-31
IL154317A0 (en) 2003-09-17
EP1317540A2 (fr) 2003-06-11
CA2419919A1 (fr) 2002-02-28
WO2002016585A2 (fr) 2002-02-28

Similar Documents

Publication Publication Date Title
NZ621196A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
WO2002050277A3 (fr) Proteines et acides nucleiques codant pour celles-ci
WO2003093316A3 (fr) Molecule a reconnaissance de la surface des cellules contenant un domaine d'immunoglobuline
WO2001005825A3 (fr) Nouveaux procedes et materiaux des angiopoietines
WO2003008446A1 (fr) Polypeptides se rapportant au transfert de signaux de recepteur de produits terminaux a glycation avancee
WO2002016585A3 (fr) Nouveaux homologues du recepteur de l'imidazoline
WO2001029217A3 (fr) Polypeptides, et polynucleotides codant ces polypeptides
WO2001081578A3 (fr) Nouvelles proteines et acides nucleiques codant ces dernieres
WO1998011234A3 (fr) Proteines kinases humaines
WO2002000691A3 (fr) Nouveaux polynucleotides et polypeptides codes par ceux-ci
WO2004085461A3 (fr) Peptide associe a une tumeur et se liant a des molecules mhc
WO2003029423A3 (fr) Polypeptides therapeutiques, acides nucleiques codant ceux-ci et procedes d'utilisation
WO2003014703A3 (fr) Acides nucleiques, polypeptides, polymorphismes nucleotidiques simples et techniques d'utilisation de ceux-ci
WO2001046231A3 (fr) Nouvelles proteines et acides nucleiques codant ces dernieres
EE200000478A (et) Peptiid, seda kodeeriv geen, diagnostiline reagent ja diagnostiline reaktiivikomplekt ning vaktsiinkasutamiseks riketsioosi ravis
WO2002030979A3 (fr) Polypeptides homologues de la thymosine, des recepteurs de l'ephrine a et de la fibromoduline, et polynucleotides codant pour ces substances
WO2002060928A3 (fr) Genes et proteines medane
WO2001059113A3 (fr) Nouvelles proteines et acides nucleiques codant ces dernieres
WO2001090187A3 (fr) Nouvelles proteines et acides nucleiques codant celles-ci
WO2001025436A3 (fr) Polypeptides de type endozepine et polynucleotides codant ces derniers
WO2002050117A3 (fr) Proteines et acides nucleiques codant ces proteines
WO2001074897A3 (fr) Proteines et acides nucleiques codant pour lesdites proteines
WO2003022867A3 (fr) Peptides derives de la proteine env superantigene (sag)de la famille herv-k18 et utilisation de ces peptides pour obtenir des anticorps innhibant l'activite des sag et produire des vaccins contre les sag
WO2002000822A3 (fr) Nouveau polypeptide, sous-unite humaine 2 $g(b) 16.5 du facteur d'initiation necessaire a la synthese proteique, et polynucleotide codant ce polypeptide
WO2003064589A3 (fr) Polypeptides therapeutiques, acides nucleiques les codant et leurs methodes d'utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 154317

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/001348

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2419919

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001283440

Country of ref document: AU

Ref document number: 2002522258

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001962245

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001962245

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载